NCT05172843 (INKA) is a NA clinical trial of Surgical knee arthroplasty in Knee Osteoarthritis, sponsored by Marius Henriksen.

Who is sponsoring NCT05172843?

NCT05172843 is sponsored by Marius Henriksen.

What drugs are being tested in NCT05172843?

Interventions in NCT05172843: Surgical knee arthroplasty, Supervised weight loss.

What condition does NCT05172843 study?

NCT05172843 studies Knee Osteoarthritis.

Is NCT05172843 still recruiting?

NCT05172843 is currently completed. Last updated 26 February 2025.

Last reviewed 2025-02-26 · How we verify

NCT05172843: INKA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intensive Diet vs Knee Arthroplasty for Knee Osteoarthritis

Completed NA Last updated 26 February 2025

What this trial tests

NA trial testing Surgical knee arthroplasty in Knee Osteoarthritis in 92 participants. Completed in 24 February 2025.

Timeline

13 January 2022

Primary endpoint
1 July 2024

24 February 2025

Quick facts

Lead sponsor	Marius Henriksen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	92
Start date	13 January 2022
Primary completion	1 July 2024
Estimated completion	24 February 2025
Sites	1 location across Denmark

Drugs / interventions tested

Surgical knee arthroplasty
Supervised weight loss

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

Marius Henriksen — full company profile →

Who can join

18 and older, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study addresses this question by comparing two recommended and potentially competing strategies in the management of obese knee OA patients: Strategy A. A 3-months waiting list followed by a 12-week Intensive supervised diet intervention; Strategy B. A 3-months waiting list followed by surgical knee arthroplasty including standard post-operative rehabilitation. The primary outcome is taken at week 38 from inclusion (baseline) corresponding to 6 months after treatment start (either surgery or intensive diet program). Outcomes are also taken at baseline, week 13 (before treatment start), week 26 (end of diet program), week 38 (primary endpoint), and week 64.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Characteristics of eligible patients with knee osteoarthritis accepting versus declining participation in a randomised trial investigating the effect of weight loss versus knee arthroplasty to explore generalisability: A cross-sectional study.
Aljuboori SM, Christensen R, Henriksen M, Bliddal H, et al · · 2025 · cited 1× · PMID 39756018 · DOI 10.1002/ksa.12546
Agreement between in vivo and ex vivo photon-counting CT measurements of subchondral trabecular bone features in patients with knee osteoarthritis.
Toft Nielsen C, Boesen M, Henriksen M, Nybing JU, et al · · 2026 · PMID 40864253 · DOI 10.1007/s00330-025-11948-9

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other Marius Henriksen trials

Trials by the same sponsor.

NCT07210931 — Self-managed vs Supervised Exercise for Knee OA · NA · not yet recruiting
NCT06846008 — The Effectiveness of a Coach-Focused Intervention on Preventing Knee Injuries in Amateur Football Players · NA · completed
NCT05215678 — Characteristics of Patients Declining INKA Trial Participation · completed
NCT04729179 — Cannabidiol for Fibromyalgia (The CANNFIB Trial) · Phase 3 · completed
NCT04322773 — Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05172843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marius Henriksen
Last refreshed: 26 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing